// App-Quantinova.ai

: Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD)

Researchers

Presenter

  • Toby Maher

Principal Investigators

  • Tamera J. Corte

  • Aryeh Fischer

  • Michael Kreuter

  • David J. Lederer

  • Maria Molina-Molina

  • Judit Axmann

  • Klaus-Uwe Kirchgaessler

  • Katerina Samara

  • Frank Gilberg

  • Vincent Cottin

Medical Centers

  • NIHR Respiratory Clinical Research Facility, Royal Brompton Hospital and Fibrosis Research Group, National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • Department of Respiratory Medicine, Royal Prince Alfred Hospital and Medical School, University of Sydney, Camperdown, New South Wales, Australia

  • University of Colorado School of Medicine, Denver, Colorado, United States of America

  • Center for Interstitial and Rare Lung Diseases, Thoraxklinik, Member of the German Center for Lung Research, University of Heidelberg, Heidelberg, Germany

  • Department of Pulmonary, Allergy & Critical Care Medicine, Columbia University Medical Center, New York, NY, United States,

  • ILD Unit, University Hospital of Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • F. Hoffmann-La Roche, Ltd./Roche (Hellas) S.A., Marousi, Greece,

Locations

  • United Kingdom

  • Australia

  • United States

  • Germany

  • Spain

  • Switzerland

  • Greece

  • France

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT03099187

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved